Consensus Protagonist Therapeutics, Inc.

Equities

PTGX

US74366E1029

Market Closed - Nasdaq 16:00:00 2024-06-14 EDT 5-day change 1st Jan Change
33.39 USD -2.79% Intraday chart for Protagonist Therapeutics, Inc. -4.05% +45.62%

Evolution of the average Target Price on Protagonist Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

428c32e33082d822c2028.NPxakfTlI-cvpAf7eeDMpv1UdqbQNZsZT93gv_z0Bus.BIkP576hTtBl7D-iDLKVy6QgT_CYW_ctJZCIyJ6HfIVczh2igLZBg3XPPw~0a0d2a099f4f66833f213d8189a25479
Protagonist Therapeutics Insider Sold Shares Worth $1,231,650, According to a Recent SEC Filing MT
Protagonist Therapeutics Insider Sold Shares Worth $280,000, According to a Recent SEC Filing MT
Protagonist Therapeutics Insider Sold Shares Worth $707,750, According to a Recent SEC Filing MT
JPMorgan Adjusts Price Target on Protagonist Therapeutics to $37 From $34, Maintains Overweight Rating MT
Capital One Starts Protagonist Therapeutics With Overweight Rating, $32 Price Target MT
JPMorgan Lowers Protagonist Therapeutics' Price Target to $34 From $36, Keeps Overweight Rating MT
JMP Securities Raises Protagonist Therapeutics' Price Target to $35 From $28, Keeps Market Outperform Rating MT
HC Wainwright Adjusts Price Target on Protagonist Therapeutics to $38 From $33, Maintains Buy Rating MT
JMP Securities Adjusts Price Target on Protagonist Therapeutics to $28 From $31, Maintains Market Outperform Rating MT
JMP Securities Adjusts Price Target on Protagonist Therapeutics to $31 From $21, Maintains Market Outperform Rating MT
HC Wainwright Lowers Price Target on Protagonist Therapeutics to $33 From $50, Maintains Buy Rating MT
JMP Securities Reinstates Protagonist Therapeutics at Market Outperform With $21 Price Target MT
Piper Sandler Adjusts Price Target on Protagonist Therapeutics to $35 From $60, Reiterates Overweight Rating MT
SVB Leerink Adjusts Protagonist Therapeutics' Price Target to $30 from $50, Keeps Outperform Rating MT
BTIG Initiates Protagonist Therapeutics at Buy With $55 Price Target MT
JMP Securities Adjusts Price Target on Protagonist Therapeutics to $70 From $60, Keeps Market Outperform Rating MT
PROTAGONIST THERAPEUTICS : JMP Securities Adjusts Price Target on Protagonist Therapeutics to $60 From $47, Maintains Market Outperform Rating MT
PROTAGONIST THERAPEUTICS : JMP Securities Adjusts Price Target on Protagonist Therapeutics to $47 From $55, Maintains Market Outperform Rating MT
PROTAGONIST THERAPEUTICS : SVB Leerink Adjusts Protagonist Therapeutics' Price Target to $50 from $35, Keeps Outperform Rating MT
PROTAGONIST THERAPEUTICS : JPMorgan Upgrades Protagonist Therapeutics to Overweight From Neutral, Sets Price Target at $55 MT
ANALYST RECOMMENDATIONS : Cigna, Halliburton, Nike, Nio, Trex... Our Logo
PROTAGONIST THERAPEUTICS : Northland Capital Markets Upgrades Protagonist Therapeutics to Outperform Rating From Market Perform, Lifts Price Target to $40 From $25 MT
PROTAGONIST THERAPEUTICS : JMP Securities Adjusts Price Target on Protagonist Therapeutics to $47 From $55, Maintains Market Outperform Rating MT
PROTAGONIST THERAPEUTICS : SVB Leerink Adjusts Protagonist Therapeutics' Price Target to $35 from $50, Keeps Outperform Rating MT
PROTAGONIST THERAPEUTICS : HC Wainwright Adjusts Protagonist Therapeutics' Price Target to $50 from $60, Keeps Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
33.39 USD
Average target price
43.83 USD
Spread / Average Target
+31.28%
High Price Target
52 USD
Spread / Highest target
+55.74%
Low Price Target
38 USD
Spread / Lowest Target
+13.81%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Protagonist Therapeutics, Inc.

JPMorgan Chase
Capital One Securities
JMP Securities
HC Wainwright
Piper Sandler
SVB Leerink
BTIG
Northland Securities
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
  1. Stock Market
  2. Equities
  3. PTGX Stock
  4. Consensus Protagonist Therapeutics, Inc.